Endoscopy 2010; 42(10): 781-789
DOI: 10.1055/s-0030-1255779
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial[*]

D.  E.  Fleischer1 , B.  F.  Overholt2 , V.  K.  Sharma1 , A.  Reymunde3 , M.  B.  Kimmey4 , R.  Chuttani5 , K.  J.  Chang6 , R.  Muthasamy6 , C.  J.  Lightdale7 , N.  Santiago3 , D.  K.  Pleskow5 , P.  J.  Dean8 , K.  K.  Wang9
  • 1Mayo Clinic, Scottsdale, Arizona, USA
  • 2Gastrointestinal Associates, Knoxville, Tennessee, USA
  • 3Ponce Gastroenterology, Ponce, Puerto Rico, USA
  • 4Tacoma Digestive Disease Center, Tacoma, Washington, USA
  • 5Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
  • 6University California, Irvine, California, USA
  • 7Columbia Presbyterian Medical Center, New York, USA
  • 8GI Pathology, Memphis, Tennessee, USA
  • 9Mayo Clinic, Rochester, Minnesota, USA
Weitere Informationen

Publikationsverlauf

submitted 23 April 2010

accepted after revision 16 May 2010

Publikationsdatum:
20. September 2010 (online)

Preview

Background and study aims: The AIM-II Trial included patients with nondysplastic Barrett’s esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4 % of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up.

Patients and methods: Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6 cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1 cm of the original extent of Barrett’s esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA.

Results: Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85 % contained lamina propria or deeper tissue (per patient, mean 30 [13], standard deviation [SD] 13). CR-IM was demonstrated in 92 % (46 / 50) of patients, while 8 % (4 / 50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95 % confidence interval [CI] 0.77 – 0.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12).

Conclusions: In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92 %) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4 / 4, 100 %) were converted to CR-IM with single-session focal RFA.

1 An oral presentation of this work was given at the American Society for Gastrointestinal Endoscopy (ASGE) Presidential Plenary Session at Digestive Diseases Week (DDW) 2010.

References

1 An oral presentation of this work was given at the American Society for Gastrointestinal Endoscopy (ASGE) Presidential Plenary Session at Digestive Diseases Week (DDW) 2010.

D. E. FleischerMD 

Mayo Clinic, Scottsdale

13400 East Shea Boulevard
Scottsdale, AZ 85259-5499
USA

Fax: +1-480-301-8673

eMail: Fleischer.David@mayo.edu